Skip to main navigation
AC Immune - World-class science that makes a difference in  patients' lives
  • About Us
    About us Our Teams Our Partners Our R&D Strategy
  • Our Science
    Our Science Pioneering Precision Medicine Technology Platforms Scientific Publications
  • Our Pipeline
    Our Pipeline Therapeutic Focus Clinical Trials
  • Investors
  • Careers
    Careers Join us
Investors
  • Why Invest
  • Key Figures
  • Share Price
  • Analyst Coverage
  • Milestones
  • Key Shareholders
  • FAQ
Press Releases
In the News
Events & Presentations
Corporate Governance
Financial Reporting
Contacts & Resources
search

Press Releases

  1. Home
  2. Investors
  3. Press Releases

PRESS RELEASES

 
Date Title View
Mar 21, 2022 AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
Mar 16, 2022 AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
Feb 28, 2022 AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
Feb 15, 2022 AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
Feb 04, 2022 AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
Feb 02, 2022 AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference
  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

Shareholder Tools

Print Page
Print Page
Email Alerts
Email Alerts
Information Request
Information Request
Contact IR
Contact IR

AC Immune SA

EPFL Innovation Park-Building B 1015 Lausanne / Switzerland
  • Phone: +41 21 345 91 21
  • Fax: +41 21 345 91 20
  • Email: info@acimmune.com
  • Home
  • About Us
  • Our Science
  • Our Pipeline
  • Investors
  • Careers

Stay in touch

Get to know us

Social Links (Redesign)

© 2022 AC Immune SA

Legal Links (Redesign)

  • Privacy policy
  • Supplier information
  • Terms of use